Comparison of the Data of a Next-Generation Sequencing Panel from K-MASTER Project with that of Orthogonal Methods for Detecting Targetable Genetic Alterations
- Authors
- Choi, Yoon Ji; Choi, Jung Yoon; Kim, Ju Won; Lim, Ah Reum; Lee, Youngwoo; Chang, Won Jin; Lee, Soohyeon; Sung, Jae Sook; Chung, Hee-Joon; Lee, Jong Won; Kang, Eun Joo; Kim, Jung Sun; Lim, Taekyu; Kim, Hye Sook; Kim, Yu Jung; Ahn, Mi Sun; Kim, Young Saing; Park, Ji Hyun; Lim, Seungtaek; Cho, Sung Shim; Cho, Jang Ho; Shin, Sang Won; Park, Kyong Hwa; Kim, Yeul Hong
- Issue Date
- Jan-2022
- Publisher
- 대한암학회
- Keywords
- High-throughput nucleotide sequencing; Pathology; Molecular; Precision medicine; Targetable gene alteration
- Citation
- Cancer Research and Treatment, v.54, no.1, pp 30 - 39
- Pages
- 10
- Indexed
- SCIE
SCOPUS
KCI
- Journal Title
- Cancer Research and Treatment
- Volume
- 54
- Number
- 1
- Start Page
- 30
- End Page
- 39
- URI
- https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/55096
- DOI
- 10.4143/crt.2021.218
- ISSN
- 1598-2998
2005-9256
- Abstract
- Purpose
K-MASTER project is a Korean national precision medicine platform that screened actionable mutations by analyzing next-generation sequencing (NGS) of solid tumor patients. We compared gene analyses between NGS panel from the K-MASTER project and orthogonal methods.
Materials and Methods
Colorectal, breast, non–small cell lung, and gastric cancer patients were included. We compared NGS results from K-MASTER projects with those of non-NGS orthogonal methods (KRAS, NRAS, and BRAF mutations in colorectal cancer [CRC]; epidermal growth factor receptor [EGFR], anaplastic lymphoma kinase [ALK] fusion, and reactive oxygen species 1 [ROS1] fusion in non–small cell lung cancer [NSCLC], and Erb-B2 receptor tyrosine kinase 2 (ERBB2) positivity in breast and gastric cancers).
Results
In the CRC cohort (n=225), the sensitivity and specificity of NGS were 87.4% and 79.3% (KRAS); 88.9% and 98.9% (NRAS); and 77.8% and 100.0% (BRAF), respectively. In the NSCLC cohort (n=109), the sensitivity and specificity of NGS for EGFR were 86.2% and 97.5%, respectively. The concordance rate for ALK fusion was 100%, but ROS1 fusion was positive in only one of three cases that were positive in orthogonal tests. In the breast cancer cohort (n=260), ERBB2 amplification was detected in 45 by NGS. Compared with orthogonal methods that integrated immunohistochemistry and in situ hybridization, sensitivity and specificity were 53.7% and 99.4%, respectively. In the gastric cancer cohort (n=64), ERBB2 amplification was detected in six by NGS. Compared with orthogonal methods, sensitivity and specificity were 62.5% and 98.2%, respectively.
Conclusion
The results of the K-MASTER NGS panel and orthogonal methods showed a different degree of agreement for each genetic alteration, but generally showed a high agreement rate.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 4. Research institute > Cancer Institute > 1. Journal Articles
- 2. Clinical Science > Department of Medical Oncology and Hematology > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.